Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,279 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Oral Complications, Ovarian Cancer, Pain, Sarcoma
Interventions: management of therapy complications, pain therapy; Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 2 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pressure Ulcers
Interventions: DermaTherapy® Linen and underpads.; Device
Lead sponsor: Precision Fabrics Group, Inc.; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostate Cancer, Urinary Tract Infection, Clostridium Difficile
Interventions: Ciprofloxacin; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Male only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2004
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Urinary Tract Infection
Interventions: Lactin-V, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 4,432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 61
States / cities: Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more

Conditions: Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions: MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 4,390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more

Conditions: HIV Infections
Interventions: Project ICARE, HCT; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HPV Infection, Vaccine-Preventable Diseases
Interventions: HPV game; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 11 Years to 14 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: COVID-19
Interventions: Hydroxychloroquine; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cervical Cancer, Precancerous Condition
Interventions: folic acid, placebo; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 120 Years · Female only
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: HIV Infections
Interventions: Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate, Pyrimethamine, Sulfamethoxazole/Trimethoprim, Sulfadoxine/Pyrimethamine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 6 more

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 24 Years
Enrollment: 16,706 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2010
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 11 more

Conditions: Monkeypox
Interventions: BNT166a; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: San Diego, California • Kansas City, Missouri • Knoxville, Tennessee + 1 more

Conditions: HIV Infections, Domestic Violence
Interventions: Trauma-Informed Toolkit; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: TRUVADA + Raltegravir; Drug
Lead sponsor: Fenway Community Health; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19 Prevention
Interventions: Q-Griffithsin 3.0, Q-Griffithsin 6.0; Drug
Lead sponsor: Kenneth Palmer; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Healthy Subject, Human Papillomavirus Infection
Interventions: carrageenan-containing gel, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 19 Years to 35 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Infection, Cesarean Delivery, Antibiotic Prophylaxis
Interventions: Cefazolin; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Pneumococcal Infections
Interventions: 13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 2,141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 26
States / cities: Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 19 more

Conditions: Baacterial Colonization, Urinary Tract Infections
Interventions: UroShield; Device
Lead sponsor: Rosenblum, Jonathan I., DPM; Individual
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Elmsford, New York

Conditions: COVID-19, Acute Respiratory Infection
Interventions: Not listed
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone, Dapsone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 43
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more

Search by objective public record fields.

Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation

Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting

Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy

Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns

Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Project ICARE: Intervening for Community Awareness, Respect, & Empowerment

Game-Based Intervention to Promote HPV Vaccination

Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers

Folic Acid Clinical Trial for the Prevention of Cervical Cancer

The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months

A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)

Connect to Protect Partnerships for Youth Prevention Interventions: Phase II

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

Using Implementation Science to Increase Pre-Exposure Prophylaxis Uptake Among African American Women

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray

Carrageenan-Containing Gel in Reducing the Rate of HPV Infection in Healthy Participants

Serum and Tissue Cefazolin Concentrations in Normal Weight Patients Undergoing Cesarean Delivery.

Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults

The Effect of Surface Acoustic Waves on the Prevention of Colonization in Longterm Indwelling Urinary Caatheters

Prophylaxis and Treatment of COVID-19

A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides